Endocrine Therapy of Advanced Breast Cancer

References

• Australian And New Zealand Breast Cancer Trials Group. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J. Clin. Oncol. 1986; 4: 186
   PubMed Web of Science ®Google Scholar
• Beex L., Pieters. Smals A., Koenders A., Benraad T., Kloppenborg P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat. Rep. 1981; 65: 179
   PubMedGoogle Scholar
• Beretta G., Tabiadon D., Tedeschi L., Luporini G. Hormontherapy of advanced breast carcinoma. Comparative evaluation of tamoxifen citrate versus medroxyprogesterone acetate. The role of tamoxifen in breast cancer, S. Iacobelli, et al. Raven Press, New York 1982; 113
   Google Scholar
• Buchanan R. B., Blamey R. W., Durrant K.R., et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J. Clin. Oncol. 1986; 4: 1326
   PubMed Web of Science ®Google Scholar
• Cavalli F., Beer M., Martz G., et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer. Report of the Swiss Group for Clinical Cancer Research. Br. Med. J. 1983; 286: 5
   PubMedGoogle Scholar
• Ettinger D. S., Allegra J., Bertino J.R., et al. Megestrol acetate v tamoxifen in advanced breast cancer. Correlation of hormone receptors and response. Sem. Oncol 1986; 13(Suppl. 4)9
   PubMed Web of Science ®Google Scholar
• Fitzpatrick P. J., Garret P. G. Metastatic breast cancer. Ovarian ablation with lower half-body irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1981; 7: 1523
   PubMedGoogle Scholar
• Fosser V. MPA Breast-Cancer Italian Clinical Trial Group. A multicentre randomized clinical trial with medroxyprogesterone acetata (MPA) at two different dosage schedules versus tamoxifen (TMX) in advanced breast cancer. Proc. 3rd Germ.-Ital. Oncol. Symp. 1984, 79
   Google Scholar
• Garcia-Giralt E., Hurteloup P., Chollet P., Bastit P., Chevalier B., Poullart P. Breast cancer first line hormonotherapy. A multicenter randomized trial comparing TAM with MAP & their sequential administration. Proc. ASCO 1987; 6(Abstr. 236)61
   Google Scholar
• Gockerman J. P., Spremulli E. N., Raney M., Logan T. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer. A Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 1986; 70: 1199
   PubMedGoogle Scholar
• Heinonen E., Alanko A., Gröhn P, Rissanen P. Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer. Breast Cancer Res. Treat. 1985; 5: 75
   PubMedGoogle Scholar
• Henderson I. C., Canellos G. P. Cancer of the breast. The past decade. New Engl. J. Med. 1980; 17: 78–302
   Google Scholar
• Ingle J. N., Ahmann D. L., Green S. J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New Engl. i. Med. 1981; 304: 16
   PubMed Web of Science ®Google Scholar
• Ingle J. N., Ahmann D. L., Green S. J., et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol. 1982; 5: 155
   PubMed Web of Science ®Google Scholar
• Ingle J. N., Green S. J., Ahmann D.L., et al. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J. Clin. Oncol. 1986; 4: 958
   PubMedGoogle Scholar
• Ingle J. N., Krook J. E., Green S.J., et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol. 1986; 4: 178
   PubMed Web of Science ®Google Scholar
• Johansson R., Nordman E. Tamoxifen and nandrolone-decanoate in treatment of metastatic breast cancer. A randomized study. Proc 3rd EORTC Breast Cancer Conference. Amsterdam Abstr 1983; IX: 18
   Google Scholar
• Kennedy B. J. Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer 1962; 15: 641
   PubMedGoogle Scholar
• Lee Y.-T. N. Therapeutic castration for advanced breast cancer. Am. J. Surg. 1971; 122: 42
   PubMedGoogle Scholar
• Lipton A., Harvey H. A., Santen R.J., et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 1982; 42((Suppl.))3434
   Google Scholar
• Lorenz L., Mechl Z. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer. Neoplasma 1985; 32: 119
   PubMedGoogle Scholar
• Matelski H., Huberman M., Zipoli T., Greene R, Lokich J. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am. J. Clin. Oncol. 1985; 8: 128
   PubMedGoogle Scholar
• Milsted R., Habeshaw T., Kaye S., et al. A randomized trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. Cancer Chemother. Pharmacol. 1985; 14: 272
   PubMedGoogle Scholar
• Morgan L. R. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Sem. Oncol. 1985; 12(Suppl. 1)43
   PubMedGoogle Scholar
• Mouridsen H. T., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 1978; 5: 131
   PubMed Web of Science ®Google Scholar
• Mouridsen H. T., Palshof T., Rose C. Therapeutic effect of tamoxifen alone versus tamoxifen in combination with gestagen and estrogen in advanced breast cancer. Rec. Results Cancer Res. 1980; 71: 169
   PubMedGoogle Scholar
• Muss H., Paschold E., Black W., et al. Megestrol acetate (M) vs. tamoxifen (T) in advanced breast cancer (ABC). A five years report. ASCO 1987; 6(Abstr 214)55
   Google Scholar
• Nagai R., Kumaoka S. Clinical evaluation of tamoxifen in advanced breast cancer (primary and recurrent) —Double blind study—. Clin. Eval. 1980; 8: 321
   Google Scholar
• Nemoto T., Patel J., Rosner D., Dao T. L. Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 1984; 53: 1333
   PubMedGoogle Scholar
• Pannuti F., Martoni A., Fruet F., Burroni P., Canova N., Hall S. Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer. The role of tamoxifen in breast cancer, S. Iacobelli, et al. Raven Press, New York 1982; 85
   Google Scholar
• Pouillart P., Jouve M., Palangie T., et al. Metastatic breast cancer. Controlled trial studying the optimal timing of hormonotherapy combined with chemoterapy (Preliminary report). ASCO 3 (Abstr. C-505) 1984; 129
   Google Scholar
• Powles T. J., Ashley S., Ford H.T., et al. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazole, used in combination or sequentially. Lancet 1984; I: 1369
   Google Scholar
• Ribeiro G. G. A clinical trial to compare the use of tamoxifen vs. stilboestrol in the treatment of postmenopausal women with advanced breast cancer. Rev Endochrine-Related Cancer 1981; 409(Suppl 9)
   Google Scholar
• Robustelli della Cuna G. Tamoxifen versus medroxyprogesterone acetate loading doses as a third-line therapy for pretreated progressive postmenopausal breast carcinoma. Cur. Chemother. Immunther. 1982; 11: 1479
   Google Scholar
• Rose C., Kamby C., Mouridsen H.T., et al. Combined endocrine treatment of post menopausal patients with advanced breast cancer. ASCO 1986; 5(Abstr. 247)64
   Google Scholar
• Rose C., Mouridsen H. T. Treatment of advanced breast cancer with tamoxifen. Rec. Results Cancer Res. 1984; 91: 230
   PubMedGoogle Scholar
• Rose C., Mouridsen H. T. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. The Danish Experience. Tumor Diagn. Ther. 1987; 8: 279
   Google Scholar
• Rubens R. D., Knight R. K. The contribution of prednisolone (P) to primary endocrine therapy (PET) in advanced breast cancer. ASCO 1985; 4(Abstr C-202)53
   Google Scholar
• Santen R. J., Samoilik E. Medical adrenalectomy for treatment of metastatic breast carcinoma. Breast Cancer: Advances in Research and Treatment, W. L. McGuire. Plenum Medical Book Company, New York 1979; 79
   Google Scholar
• Silva A. Medroxyprogesterone acetate versus tamoxifen in advanced breast cancer. Proc 3rd ECCO. (Poster 13338). Stockholm 1985
   Google Scholar
• Smith I. E., Harris A. L., Morgan M., et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. Br. Med. J. 1981; 283: 1432
   PubMed Web of Science ®Google Scholar
• Stewart H. J., Forrest A. P. M., Gunn J. M., et al. The tamoxifen trial—A double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Eur. J. Cancer 1980; 83(Suppl 1)
   Google Scholar
• Stewart J. F., Rubens R. D., King R. J. B., et al. Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur. J. Cancer Clin. Oncol. 1982; 18: 1307
   PubMedGoogle Scholar
• Stuart- Harris R. C., Smith I E. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat. Rev. 1984; 11: 189
   PubMedGoogle Scholar
• Taylor S. G., Gelman R. S., Falkson G., Cummings F. J. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann. Intern. Med. 1986; 104: 455
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Lippman M. E., Edwards B. K., Cassidy J. G. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann. Intern. Med. 1983; 98: 139
   PubMed Web of Science ®Google Scholar
• Twito D. I., Ingle J. N., Chang M.N., et al. Randomized trial of tamoxifen (TAM) alone or combined with fluoxymesterone (FLU) in postmenopausal women with metastatic breast cancer. ASCO 1986; 5(Abstr. 242)62
   Google Scholar
• van Veelen H., Willemse P. H. B., Tjabbes T., Schweitzer M. J. H., Sleijfer D. T. Oral high-dose medroxyprogesterone acetate versus tamoxifen. Cancer 1986; 58: 7
   PubMed Web of Science ®Google Scholar
• Viladiu P., Alonso M. C., Avella A., et al. Chemotherapy versus chemotherapy plus hormontherapy in postmenopausal advanced breast cancer patients. A randomized trial. Cancer 1985; 56: 2745
   Google Scholar
• Wallgren A., Glas U., Buchanan R., et al. A comparison of ‘nolvadex’ (tamoxifen) monotherapy with ‘nolvadex’ plus ‘halotestin’ (fluoxymesterone) in the treatment of advanced breast cancer in postmenopausal women. Proc 14th Int. Cancer Congr. (Abstr. 4826). Budapest 1986. 51. Westerberg H.: Tamoxifen and fluoxymesterone in advanced breast cancer. A controlled clinical trial.x. Cancer Treat. Rep. 1980; 64: 117
   PubMedGoogle Scholar